Veterinary Dermatology Market

The global veterinary dermatology market is projected to reach USD 30.31 billion by 2030 from USD 18.59 billion in 2025, at a CAGR of 8.5%. Growth in this market is largely driven by the increasing companion animal population and pet ownership, and growing concerns about infectious zoonotic diseases. There is an increased adoption of pet insurance and high animal healthcare expenditure, along with rising awareness initiatives by government and animal welfare organizations, which are further boosting the market growth.

To know about the assumptions considered for the study download the pdf brochure

The prominent players in the veterinary dermatology market include Elanco Animal Health Incorporated (US), Merck & Co., Inc. (US), Virbac (France), Zoetis Inc. (US), Boehringer Ingelheim International GmbH (Germany), Vetoquinol (France), Dechra Pharmaceuticals plc (UK), Hester Biosciences Limited (India), PetIQ, Inc. (US), Ourofino Saude Animal (Brazil), Swedencare (Sweden), Orion Corporation (Finland), Norbrook (Ireland), Ceva Sante Animale (France), Bimeda, Inc. (Ireland). These players are constantly involved in the development of new products and adopting growth strategies like acquisitions, mergers, collaboration, etc. to strengthen their market reach.

Zoetis Inc.

Zoetis Inc. (US) discovers, develops, manufactures, and commercializes vaccines and medicines for livestock and companion animals. The company operates through three business segments: Companion Animals, Livestock, and Contract Manufacturing & Human Health. The company offers products related to dermatology for animals through both the Companion Animals and Livestock segments. The company operates in 70 countries, and its products are sold in over 120 countries through its distribution networks. Some of its significant subsidiaries are Alpharma Animal Health Company (US), Fort Dodge Asia Exports, Inc. (US), and Jilin Pfizer Guoyuan Animal Health Co., Ltd. (China). The company also heavily invest on product launches and developments. For example, in October 2023, the company launched Apoquel Chewable (Tablet), the first and only chewable treatment for the control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs in the US.

Related Reports:

Veterinary Dermatology Market by Route of Administration, Product type (Antibacterial, Antifungal, Antiparasitic Drugs, Monoclonal Antibodies), Condition type (Parasitic Infections, Infectious Diseases, Skin Cancer), Animal type - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]